← Human Trials & Peer-Reviewed Studies
Evaluation of Urinary Aquaporin 2 and Plasma Copeptin as Biomarkers of Effectiveness of Desmopressin Acetate for the Treatment of Monosymptomatic Nocturnal Enuresis
Plain-language guide to PMID 28457803 (2017): clinical trial study of Vasopressin and Desmopressin in 32 children.
Key Facts
- PMID
- 28457803
- Journal
- The Journal of urology
- Year
- 2017
- Study type
- Clinical Trial
- Authors
- Hara T et al. (6 authors)
- DOI
- 10.1016/j.juro.2017.04.088
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vasopressin and Desmopressin, published as a clinical trial.
Desmopressin is a synthetic V2 specific analogue of antidiuretic hormone (arginine vasopressin) that is widely used as first line treatment for monosymptomatic nocturnal enuresis.
Because arginine vasopressin is unstable, the researchers prospectively measured the major urine concentration factor aquaporin 2 and serum copeptin (as a surrogate marker for vasopressin) in patients with monosymptomatic nocturnal enuresis, and evaluated whether they are useful for predicting desmopressin treatment outcome.
Who Took Part
The study group was 32 children.
The age groups tagged for this paper are children, both men and women.
The study included 32 children 6 to 11 years old with monosymptomatic nocturnal enuresis and nocturnal polyuria.
Exclusion criteria were daytime urinary symptoms and underlying diseases causing nocturnal enuresis.
How the Study Was Run
Day/night ratios of plasma copeptin and urinary aquaporin 2 were measured during desmopressin treatment.
What Was Measured
The subject headings attached to it are Antidiuretic Agents, Aquaporin 2, Deamino Arginine Vasopressin, Glycopeptides, Nocturnal Enuresis, Predictive Value of Tests and Recurrence.
The authors tagged it with the keywords pediatrics.
What This Means in Plain Language
This is a clinical trial of Vasopressin and Desmopressin in 32 children.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2017 (The Journal of urology), a journal based in United States.
More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.
Our Notes on the Compounds
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.